Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Can-Fite Biopharma Ltd ADR (CANF)

Can-Fite Biopharma Ltd ADR (CANF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Can-Fite BioPharma Reports 8-Year Survival with Namodenoson in Liver Cancer Patient and Announces Phase III Study Enrollment Quiver Quantitative, Inc. - Wed Dec 4, 4:16PM CST

Can-Fite announces an 8-year complete response in advanced liver cancer patient treated with Namodenoson; Phase III study enrolling now.Quiver AI SummaryCan-Fite BioPharma Ltd. announced promising results...

CANF : 1.4800 (+2.78%)
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESSWIRE - Fri Nov 22, 3:00AM CST

ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the...

SXTP : 1.2600 (-10.64%)
CANF : 1.4800 (+2.78%)
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV Newsfile - Mon Apr 1, 6:16AM CDT

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New...

CANF : 1.4800 (+2.78%)
Happy Thanksgiving, Uncle Sam! Baystreet - Fri Nov 17, 2023

Monday U.S. Economic Lookahead U.S. leading economic indicators (Oct.) Featured Earnings Agilent ...

WN.TO : 226.67 (-0.16%)
A : 134.51 (+0.99%)
TCOM : 72.44 (-0.18%)
KEYS : 163.22 (+2.11%)
NVDA : 134.70 (+3.08%)
LOW : 247.72 (+1.31%)
MDT : 81.03 (+1.30%)
DE : 432.49 (+1.37%)
GDS : 19.80 (+2.80%)
BMA : 96.70 (+1.53%)
HTHT : 33.47 (+0.90%)
LEXX : 2.23 (+0.90%)
Author
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding MarketBeat - Tue May 2, 2023

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

CANF : 1.4800 (+2.78%)
BMY : 57.33 (+1.83%)
LLY : 767.76 (+1.35%)
MRK : 98.05 (-1.48%)
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists Business Wire - Tue May 2, 2023

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.4800 (+2.78%)
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization Business Wire - Mon Apr 24, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.4800 (+2.78%)
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment Business Wire - Mon Apr 10, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.4800 (+2.78%)
Can-Fite Reports 2022 Financial Results & Provides Clinical Update Business Wire - Thu Mar 30, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 1.4800 (+2.78%)
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson Business Wire - Thu Mar 16, 2023

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today...

CFBI : 10.08 (-0.30%)
CANF : 1.4800 (+2.78%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot